COMPANY PROFILE / iPS CELLS & REGENERATIVE MEDICINE
Beam Therapeutics
A base-editing company changing a single DNA letter without cutting the strand, pursuing both an ex vivo blood stem cell therapy and an in vivo liver therapy
Beam is a base-editing specialist that does not work with iPS cells. It earns a place in this field because its therapy that edits the patient's own blood stem cells and returns them (risto-cel), the same broad approach as CASGEVY, uses a method that does not cut the DNA. It is also developing a technology that replaces the conditioning drugs with an antibody (ESCAPE) and an approach that edits blood stem cells directly inside the body. The BLA for risto-cel is planned for the end of 2026 at the earliest. This profile concentrates on what the company invests in, who it works with and what it is aiming for.
- Beam in 30 seconds, and where it stands in iPS cells and regenerative medicine
- The logo and how the name is written
- Where the company sits in iPS cells and regenerative medicine
- Company scale
- Resources committed to iPS cells and regenerative medicine
- Track record so far
- Plans ahead
- What the company is aiming for
- Partnership map for genome editing and blood stem cell therapy
- Technologies and products on offer
- The risks this company carries
- Glossary, references and claim-to-source audit
1. Beam in 30 seconds, and where it stands in iPS cells and regenerative medicine
Massachusetts, U.S.238 Main Street (cover of the 10-K)
(both outside and inside the body)Changes a single DNA letter without cutting the DNA
BEAM-302 (AATD)Both in Phase 1/2. BLA for risto-cel at the end of 2026 at the earliest
Beam is a base-editing company: it changes a single DNA letter without cutting the strand. It works along two main lines, neither involving iPS cells: "risto-cel", in which the patient's own blood stem cells are edited outside the body and returned, and "BEAM-302" and other programmes that edit the liver inside the body using lipid nanoparticles (LNPs) Sourced.
Risto-cel, like CASGEVY, edits autologous blood stem cells, but the editing method is different (base editing rather than a method that cuts the DNA). Beam is also developing a technology that replaces the conditioning drugs with an antibody (ESCAPE). We found no product in Beam's 10-K or 10-Q that uses iPS cells or cells from another person Not yet confirmed.
2. The logo and how the name is written
A note on names: the legal entity is Beam Therapeutics Inc. We could not confirm an official Japanese-language rendering in the material we used, so this article uses the English name throughout. "Beam" is also an ordinary English word, so in this article it always means the company when written with a capital B. Risto-cel (formerly BEAM-101) is the same product from the same company; only the name has changed. Its partners Pfizer, Eli Lilly and Bristol Myers Squibb are all separate companies.
Official site: https://beamtx.com/3. Where the company sits in iPS cells and regenerative medicine
| Therapeutic approach | Where Beam fits | Status | Category |
|---|---|---|---|
| Genome editing (base editing, outside the body) | risto-cel (BEAM-101). The patient's own blood stem cells are edited by electroporation and returned after conditioning | Phase 1/2 (BEACON). BLA at the end of 2026 at the earliest | Sourced |
| Genome editing (base editing, inside the body) | BEAM-302 (AATD), BEAM-301 (GSDIa), BEAM-304 (PKU). Delivered to the liver in LNPs | BEAM-302 and BEAM-301 are in Phase 1/2; the IND for BEAM-304 was accepted (June 2026) | Sourced |
| Editing blood stem cells inside the body | An LNP that targets blood stem cells is in development. Prioritised as the "next wave" in sickle cell disease | Lead optimisation | Sourced |
| Replacing conditioning with an antibody (ESCAPE) | BEAM-103 (anti-CD117 antibody). Usable with both ex vivo and in vivo approaches | Phase 1 (healthy adults) | Sourced |
| iPS-cell-derived cells | No mention of "iPS" in the 10-K or 10-Q | Could not be confirmed | Not yet confirmed |
| Mesenchymal stem cells and tissue engineering | Not described | Could not be confirmed | Not yet confirmed |
Our explainers on genome editing, off-target effects and safety assessment, genome-editing therapies for blood disorders, lipid nanoparticles and mRNA give the background to each row of the table.
4. Company scale
Figures are in U.S. dollars and the fiscal year ends in December. Beam has no product sales, and its revenue comes from collaboration agreements Sourced.
| Measure (US$ millions) | 2024 | 2025 | First half of 2026 |
|---|---|---|---|
| Collaboration revenue | 63.5 | 139.7 | 32.2 |
| Research and development expense | 367.6 | 409.6 | 199.6 |
| General and administrative expense | 111.5 | 113.8 | 66.4 |
| Operating loss | 415.6 | 383.7 | 233.8 |
| Gain on sale of Orbital stake | - | 255.1 | - |
| Net loss | 376.7 | 80.0 | 217.0 |
The 2025 net loss was small, at US$80.0 million, because Bristol Myers Squibb's acquisition of Orbital produced a US$255.1 million gain on the sale of Beam's shares. The operating loss of 383.7 was about the same as the year before Sourced. The 10-K attributes the rise in 2025 collaboration revenue mainly to US$109.1 million recognised on completion of the Pfizer collaboration.
Beam had 511 employees at 31 December 2025 (399 in R&D, 112 in administration, and 118 with an M.D. or Ph.D.) Sourced.
The figures above are for the whole company. They do not measure the size of any iPS cell or regenerative medicine business. The first-half 2026 operating loss of 233.8 is the difference between the 10-Q's collaboration revenue of 32.2 and operating expenses of 266.0, calculated by us Our calculation. Cash is about US$1.2 billion, but the company says it covers "at least the next 12 months" of expenses, which is a shorter period than CRISPR Therapeutics' (more than 24 months) Sourced.
5. Resources committed to iPS cells and regenerative medicine
There are no figures for iPS cells and regenerative medicine alone. We show the resources relevant to genome editing and blood stem cell therapy, along four lines.
| Resource | Details | Category |
|---|---|---|
| People (company-wide) | 511 (31 December 2025): 399 in R&D, 112 in administration, 118 with an M.D. or Ph.D. | Sourced |
| People (iPS cells and regenerative medicine) | No dedicated team is described | Could not be confirmed |
| Sites | A research building of about 130,258 sq ft in Cambridge (leased to 2034). A cGMP manufacturing building of about 100,000 sq ft in Research Triangle Park, North Carolina (leased to 2037), designed to make both ex vivo edited cell therapies and LNP products for use inside the body | Sourced |
| Money (R&D expense) | US$409.6 million company-wide (2025); US$199.6 million in the first half of 2026 | Sourced |
| Money (financing) | Cash of about US$1.2 billion (30 June 2026). Net proceeds of US$470.5 million from the March 2025 equity raise. A loan agreement with Sixth Street in February 2026 (US$100.0 million initially, with up to US$300 million more depending on the filing, approval and sales of risto-cel) | Sourced |
| Investments and acquisitions | Held 75 million shares of Orbital Therapeutics and received US$255.1 million on its acquisition by BMS in December 2025 (with up to about US$26.3 million more from escrow) | Sourced |
| In-licensing | An exclusive licence to base-editing patents from Harvard University (2017). The first success-fee measurement gave US$15.0 million (paid in shares). An option to obtain exclusive licences to patents from Editas (Cas9 and Cas12a). A cross-licence with Prime Medicine | Sourced |
| Out-licensing and collaboration | Pfizer (from December 2021; opted in to a liver candidate in December 2025), Apellis (from June 2021; opted in to the FcRN programme, fee of US$3.8 million), Verve / Lilly (in October 2023 Lilly acquired the rights under the Verve agreement, with US$200.0 million upfront to Beam and up to US$350.0 million), and Orbital | Sourced |
| Universities, research institutes and public funding | Harvard University (patents) and the Broad Institute (the party to whom success fees are owed). No public funding or grants could be confirmed in the material we used | Sourced / could not be confirmed |
6. Track record so far
| When | What happened | What it means |
|---|---|---|
| January and June 2017 | Begins operations. In June, exclusive licence agreement with Harvard University for base-editing patents | Secured the rights to the editing tool |
| April 2019 | Exclusive licence agreement with Verve for base editing against three cardiovascular targets | Out-licensed an area it does not pursue itself |
| June and December 2021 | Research collaboration with Apellis on complement-related targets in June. Four-year research collaboration with Pfizer in December (in vivo base editing, three targets) | Partnerships with large companies began |
| August 2022 | Phase 1/2 trial of risto-cel (BEACON) begins (ClinicalTrials.gov start date: 30 August 2022) | An ex vivo edited cell therapy entered the clinic |
| October 2023 | Lilly acquires the rights under the Verve agreement. US$200.0 million to Beam, up to US$350.0 million | Turned contractual rights into cash |
| June 2024 | Phase 1/2 trial of BEAM-302 begins (ClinicalTrials.gov start date: 19 June 2024) | In vivo editing entered the clinic |
| March 2025 | Equity raise with net proceeds of US$470.5 million | Thickened its funding |
| December 2025 | Presents data on 31 people treated with risto-cel at ASH. Pfizer opts in to a liver candidate. BMS acquires Orbital and Beam receives US$255.1 million. A long-term follow-up study of BEACON also begins | Several milestones came together |
| February 2026 | Loan agreement with Sixth Street (US$100.0 million initially) | An additional borrowing facility tied to the filing and approval of risto-cel |
| March 2026 | Presents updated data for BEAM-302. Based on FDA advice, aims for an accelerated approval path with a 12-month AAT measure at 60 mg as the primary endpoint | The design leading to an application for approval took shape |
| May-June 2026 | Biogen acquires Apellis in May. The IND for BEAM-304 (PKU) is accepted by the FDA in June | A partner was reorganised and a new product started |
| July 2026 | First patient dosed in the main cohort of BEAM-302 (an expansion of about 50 people) | The trial supporting an application for approval began |
7. Plans ahead
at the earliestUpdated BEACON data also by the end of 2026
about 50 peopleFirst patient dosed in July 2026
reported in 2026Phase 1/2 in GSDIa
Phase 1/2IND accepted in June 2026
(healthy adults)Dosing due to finish in the first half of 2026
Of the items in the table, the company gives timing for the risto-cel BLA and the main cohort of BEAM-302 Sourced. All are plans, not guarantees of approval or launch Not yet confirmed.
None of the following appears in the material we used Not yet confirmed.
The timing of approval and the price of risto-cel / the timing of an application for approval of BEAM-302 / the Phase 1 results of BEAM-103 / any plan to enter iPS cells and regenerative medicine. Timings and prices in press reports cannot be verified against primary sources, so this article does not use them.
8. What the company is aiming for
This section includes things the company does not say directly. We set them out as inferences within what the primary sources support, with the evidence for each.
| What the evidence suggests | Primary information it rests on | Category |
|---|---|---|
| In sickle cell disease, it intends to move from editing outside the body to editing inside it | The 10-K states that, as the next wave in sickle cell disease, it is prioritising in vivo delivery to blood stem cells | Sourced |
| The reason is to avoid the burdens of conditioning and cell collection | The 10-K says ex vivo editing requires conditioning such as busulfan, and ESCAPE aims at "non-genotoxic" conditioning. The company does not state its reason for the shift, however | Inference |
| The first commercial product will be risto-cel | The BLA is planned for the end of 2026 at the earliest. Sixth Street's additional borrowing facility is tied to acceptance of the risto-cel BLA, approval and sales | Inference |
| It values owning its own manufacturing | It owns a cGMP manufacturing building of about 100,000 sq ft and says early clinical trials will be supplied mainly in house | Sourced |
| Areas it does not pursue itself it out-licenses to large companies and turns into cash | Agreements with Pfizer, Lilly and Orbital (BMS) brought in revenue and US$255.1 million in 2025 | Inference |
For readers of this series, we read the most important item as ESCAPE, which replaces the conditioning drugs with an antibody Inference. Ex vivo editing therapies (CASGEVY included) need conditioning that destroys bone marrow cells with drugs to make room for the edited stem cells. Beam's 10-K describes ESCAPE as a technology that combines "antibody-based conditioning with stem cells edited at several genes", and says it could enable a "non-genotoxic" treatment strategy Sourced. The stage reached is the BEAM-103 Phase 1 in healthy adults, and no effect in patients has yet been shown Not yet confirmed. The 10-K also notes that the contractual definition of Beam's field includes "conditioning for cell transplantation", which shows that replacing conditioning is a challenge for cell transplantation as a whole.
9. Partnership map for genome editing and blood stem cell therapy
The thing to notice in this map is that almost all of Beam's partners have been acquired, or are now acquirers. Verve was acquired by Lilly, Orbital by BMS and Apellis by Biogen Sourced. The counterparties in Beam's collaborations change each time the large drug companies reorganise.
10. Technologies and products on offer
| Product | How it works | Target | Status |
|---|---|---|---|
| risto-cel (BEAM-101) | The patient's own blood stem cells are base-edited by electroporation (an edit that raises fetal hemoglobin). Conditioning with busulfan | Severe sickle cell disease | Phase 1/2 (BEACON). FDA orphan and RMAT designations. BLA at the end of 2026 at the earliest |
| BEAM-302 | Base editor delivered in a liver-targeted LNP to correct the E342K mutation in the SERPINA1 gene. Single dose | Alpha-1 antitrypsin deficiency (AATD) | Phase 1/2. Agreed an accelerated approval path with the FDA |
| BEAM-301 | Base editor delivered in a liver-targeted LNP to correct the R83C mutation in the G6PC gene | Glycogen storage disease type Ia (GSDIa) | Phase 1/2 |
| BEAM-304 | Base editor delivered in a liver-targeted LNP | Phenylketonuria (PKU) | IND accepted (June 2026) |
| BEAM-103 (ESCAPE) | An anti-CD117 antibody that replaces the conditioning drugs | Hematopoietic stem cell transplantation in general | Phase 1 (healthy adults) |
Trial results (figures from company statements as recorded in the 10-K and 10-Q; not peer-reviewed papers)
| Trial | Population and design | Result | Time point and caveats |
|---|---|---|---|
| BEACON (risto-cel) | 31 people with severe sickle cell disease (interim data at ASH 2025). Single-arm, open-label | Mean HbF above 60% and HbS below 40%. No severe vaso-occlusive crises reported by the treating clinicians after dosing. Median neutrophil engraftment at 17.5 days | As of 6 August 2025, follow-up 0.3 to 20.4 months. No comparison group. One person died of respiratory failure 4 months after dosing (the investigator judged it likely related to the conditioning drug busulfan) |
| BEAM-302 Phase 1/2 (March 2026 update) | AATD. 29 people dosed (24 in Part A, 5 in Part B), followed up to 18 months as of 10 February 2026. Safety assessed in 26 people given a single dose | In the 60 mg group of Part A, mean total AAT at steady state was 16.1 µM, mutant Z-AAT fell by a mean of 84%, and the share of circulating AAT that was newly made normal M-AAT was 94% | No comparison group. In the repeat-dose group (3 people), one person had a Grade 4 ALT elevation after the second dose (no symptoms, no treatment needed) |
Beam has two routes for delivery, which differ: electroporation (electrical pulses that get a base editor into cells) outside the body and LNPs inside it Sourced. For electroporation, the dedicated equipment, buffers and single-use containers that get the editor in efficiently without damaging the cells bear on quality, while for LNPs the lipid composition and the uniformity of particle size are decisive Inference.
The 10-K says it has put mRNA manufacturing and cell processing in place as in-house capabilities, and that its cGMP building of about 100,000 sq ft is designed for both ex vivo edited cell therapies and non-viral products for use inside the body Sourced. ESCAPE's antibody (anti-CD117) is also an attempt to replace the small-molecule conditioning drug with an antibody medicine, which changes the kind of materials used at a fundamental level.
11. The risks this company carries
| Risk | Details | Category |
|---|---|---|
| No product yet | No product sales and no approved product. The risto-cel BLA is the first milestone | Sourced |
| Safety linked to conditioning | In BEACON, one death was judged likely to be related to the conditioning drug busulfan. Ex vivo editing therapies presuppose conditioning | Sourced |
| Safety of in vivo editing | In the repeat-dose group of BEAM-302, one person had a Grade 4 ALT elevation (no symptoms). No serious adverse events were reported in the 26 people given a single dose | Sourced |
| Competition | In sickle cell disease, the 10-K names many competitors, including CRISPR Therapeutics, Vertex, Genetix (formerly bluebird bio) and Novartis. Some already have approved therapies | Sourced |
| Patents | The base-editing patents are exclusively licensed from Harvard University, which can license third parties in certain circumstances. Cas9 and Cas12a depend on an option from Editas | Sourced |
| Funding and borrowing | Cash is about US$1.2 billion, but the period the company says it covers is 12 months. The Sixth Street loan carries a liquidity covenant (a minimum of US$40 million, rising with additional borrowing) | Sourced |
| Partners' reorganisation | Verve (Lilly), Orbital (BMS) and Apellis (Biogen) have been acquired. Whether the contracts continue depends on the acquirers' policies | Sourced / Inference |
12. Glossary
- Base editing
- An editing method that changes a single base (A, C, G or T) into another without cutting both strands of the DNA.
- Electroporation
- A method that opens temporary pores in the cell membrane with electrical pulses so that an editing agent can get in.
- HbF (fetal hemoglobin)
- An oxygen-carrying protein made before birth. Higher levels are thought to prevent red blood cells from sickling.
- Conditioning
- Using drugs before treatment to reduce the cells in the bone marrow and make room for the edited cells. It places a heavy burden on the body.
- ESCAPE
- A technology Beam is developing that uses an antibody for conditioning. It aims at conditioning that does not damage DNA.
- AATD
- Alpha-1 antitrypsin deficiency. An inherited disease in which a protein made in the liver is abnormal, causing damage to the lungs and liver.
- LNP (lipid nanoparticle)
- A tiny particle made of lipids that wraps nucleic acids and delivers them into cells.
- BLA / RMAT
- A BLA is the U.S. application for approval of a biologic. RMAT is an FDA designation that speeds up the development of regenerative medicine.
- Accelerated approval
- A U.S. pathway that approves a drug first on the strength of a surrogate marker (biomarker). A confirmatory trial is required afterwards.
- Opt-in
- When a partner exercises its right to take part in development.
13. References
- Beam Therapeutics Form 10-K for the fiscal year ended December 31, 2025 (filed with the U.S. SEC on 24 February 2026). Base-editing business, clinical work on risto-cel (BEAM-101) and BEAM-302 and others, collaboration agreements, patent licences, sites, headcount and financials. https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm
- Beam Therapeutics Form 10-Q for the quarterly period ended June 30, 2026 (filed with the U.S. SEC on 4 August 2026). BEAM-302 data, acceptance of the BEAM-304 IND, the current status of collaborations, the Sixth Street loan, and first-half 2026 financials. https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm
- ClinicalTrials.gov NCT05456880, BEACON: a study evaluating BEAM-101 in severe sickle cell disease (sponsor: Beam Therapeutics). Start date 30 August 2022, Phase 1/2. https://clinicaltrials.gov/study/NCT05456880
- ClinicalTrials.gov NCT07373639, a long-term follow-up study of participants who received BEAM-101. Start date 15 December 2025, estimated enrolment 50. https://clinicaltrials.gov/study/NCT07373639
- ClinicalTrials.gov NCT06389877, a study evaluating BEAM-302 in alpha-1 antitrypsin deficiency. Start date 19 June 2024, Phase 1/2, estimated enrolment 106. https://clinicaltrials.gov/study/NCT06389877
- Beam Therapeutics Official website (used to check the company overview and the logo). https://beamtx.com/
14. Claim-to-source audit
| Claim in the article | Category | Source |
|---|---|---|
| Legal name, Cambridge headquarters, Nasdaq: BEAM, start of operations in January 2017 | Sourced | References 1 and 6 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://beamtx.com/ |
| Collaboration revenue, R&D expense, G&A expense, operating loss and net loss (2024 and 2025), and US$109.1 million of revenue on completion of the Pfizer collaboration | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| First-half 2026 financials, cash of about US$1.2 billion, and the statement that it covers 12 months of expenses | Sourced | Reference 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm |
| US$255.1 million gain on the sale of the Orbital stake (BMS acquisition, December 2025) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| 511 employees (31 December 2025), 399 in R&D, 118 with an M.D. or Ph.D. | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| Cambridge building of about 130,258 sq ft and Research Triangle Park cGMP building of about 100,000 sq ft | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| The March 2025 equity raise (net proceeds of US$470.5 million) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| The Sixth Street loan agreement (US$100.0 million initially, up to US$300 million more, interest rate, covenants) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm |
| How risto-cel works, the design of the BEACON trial, a BLA at the end of 2026 at the earliest, RMAT and orphan designations | Sourced | References 1, 2 and 3 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm https://clinicaltrials.gov/study/NCT05456880 |
| BEACON interim data (31 people, HbF above 60%, HbS below 40%, engraftment at 17.5 days, one death) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm |
| How BEAM-302 works, the start of the trial, the March 2026 data (84% reduction in Z-AAT and others), the accelerated approval path, and the start of the main cohort in July 2026 | Sourced | References 2 and 5 https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm https://clinicaltrials.gov/study/NCT06389877 |
| The BEACON long-term follow-up study (NCT07373639, started 15 December 2025) | Sourced | Reference 4 https://clinicaltrials.gov/study/NCT07373639 |
| BEAM-301, BEAM-304 (IND accepted June 2026) and BEAM-103 (ESCAPE, Phase 1) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm |
| Prioritising in vivo delivery to blood stem cells as the next wave in sickle cell disease | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| Exclusive licence from Harvard University (2017), US$15.0 million success fee, the Editas option, and the cross-licence with Prime Medicine | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| Pfizer's December 2025 opt-in and Apellis's opt-in to FcRN, including the US$3.8 million payment and Biogen acquisition | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm |
| Verve / Lilly (October 2023, US$200.0 million and up to US$350.0 million, a cumulative US$50.0 million by June 2026) | Sourced | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm |
| Orbital / BMS (a non-exclusive cross-licence, acquisition completed in December 2025) | Sourced | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm |
| First-half 2026 operating loss of 233.8 (the difference between 32.2 and 266.0) | Our calculation | Reference 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm Subtraction performed in this article |
| The three types of company (large pharma and strategic partners / genome editing and gene therapy / iPS cell and cell therapy) | Our calculation | This article's own classification. Example companies are drawn from those covered in this series |
| Use of iPS cells, mesenchymal stem cells, and any allogeneic cell therapy of its own | Not yet confirmed | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm Not stated in the 10-K or 10-Q. This article does not conclude that they do not exist either |
| The timing of approval and price of risto-cel, the timing of a BEAM-302 application, and the results of BEAM-103 | Not yet confirmed | Reference 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm Not stated in the 10-Q. Figures from press reports are not used |
| Public funding and grants | Not yet confirmed | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm Not stated in the 10-K |
| The reading that the reason for moving from ex vivo to in vivo is to avoid the burdens of conditioning and collection | Inference | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm The company does not state its reason. This article's interpretation |
| The reading that the first commercial product will be risto-cel | Inference | References 1 and 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm This article's interpretation |
| The reading that it out-licenses areas it does not pursue itself and turns them into cash | Inference | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm This article's interpretation |
| The reading that ESCAPE could change the problem of conditioning | Inference | Reference 1 https://www.sec.gov/Archives/edgar/data/1745999/000119312526065194/beam-20251231.htm This article's interpretation. No effect in patients has been confirmed |
| The reading that partners' reorganisation affects whether contracts continue | Inference | Reference 2 https://www.sec.gov/Archives/edgar/data/1745999/000119312526331541/beam-20260630.htm This article's interpretation |
| The reading that the materials for electroporation and LNPs determine quality | Inference | This article's interpretation (from a materials and process viewpoint) |
Last updated 1 October 2026 / Troy Technical
Every figure in this article comes from the statutory filings Beam has made with the U.S. Securities and Exchange Commission (SEC) and from ClinicalTrials.gov. The clinical trial data are company statements as confirmed in the 10-K and 10-Q, not peer-reviewed papers. No research-firm estimates or press-based figures have been used. Passages marked "Inference" are this article's interpretation of the primary sources, not statements made by the company. This article summarises a company's activities; it does not recommend any treatment and is not medical advice.